Viewing Study NCT06172595


Ignite Creation Date: 2025-12-24 @ 1:41 PM
Ignite Modification Date: 2025-12-24 @ 1:41 PM
Study NCT ID: NCT06172595
Status: RECRUITING
Last Update Posted: 2024-12-03
First Post: 2023-12-07
Is Possible Gene Therapy: False
Has Adverse Events: False

Brief Title: FET PET in Differentiating Tumour Progression From Pseudoprogression in High Grade Glioma
Sponsor: Singapore General Hospital
Organization:

Study Overview

Official Title: 18F-FET (O-(2-[18F]Fluoroethyl)-L-tyrosine) PET in Differentiating Tumour Progression From Pseudoprogression in High Grade Gliomas
Status: RECRUITING
Status Verified Date: 2024-11
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: FET PET in HGG
Brief Summary: The goal of this clinical trial is to evaluate the performance characteristics of O-(2-\[18F\]fluoroethyl)-L-tyrosine (FET) PET in differentiating pseudoprogression from tumour progression in patients with equivocal conventional imaging and determine the sensitivity and specificity of \[18F\]FET-PET in delineating disease. The main question\[s\] it aims to answer are:

* whether 18F-FET-PET will demonstrate high diagnostic accuracy to detect true tumour progression
* whether we can optimise the threshold cut-offs for TBRmax and other relevant parameters in discriminating pseudoprogression and disease progression Participants will undergo a limited 18F-FET PET/CT of the brain in SGH.
Detailed Description: None

Study Oversight

Has Oversight DMC: True
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: